
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 21, 2020, titled "Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg".
Filed with NSE · · 2 pages · English

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 21, 2020, titled "Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg".
Glenmark Pharmaceuticals Limited on 6ix
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals